<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089128</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000378047</org_study_id>
    <secondary_id>MUSC-100615</secondary_id>
    <secondary_id>PHARMACIA-440EONCO020298</secondary_id>
    <secondary_id>MUSC-HR-10212</secondary_id>
    <nct_id>NCT00089128</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer</brief_title>
  <official_title>Phase II Study Of Gemcitabine And CPT-11 (Irinotecan) In Locally Advanced Or Metastatic Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different
      ways to stop tumor cells from dividing so they stop growing or die. Combining more than one
      drug may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving gemcitabine together with irinotecan
      works in treating patients with locally advanced or metastatic bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine response in patients with locally advanced or metastatic transitional cell
           carcinoma of the bladder treated with gemcitabine and irinotecan.

      Secondary

        -  Determine the duration of response in patients treated with this regimen.

        -  Determine the tolerance to and toxicity of this regimen in these patients.

        -  Determine the median and progression-free survival of patients treated with this
           regimen.

      OUTLINE: Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on
      days 1 and 8. Courses repeat every 21 days in the absence of disease progression or
      unacceptable toxicity. Patients with responding disease receive 2 additional courses beyond
      best response.

      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Proportion</measure>
    <time_frame>From registration until time of complete response or partial response</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From registration until disease progression among patients who had at least a partial response.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events as Assessed by NCI CTC Version 2.0</measure>
    <time_frame>From the day of first dose until the end of study, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Time between registration and disease progression or death, whichever comes first.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine and Irnotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Gemcitabine and Irnotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Gemcitabine and Irnotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed transitional cell carcinoma of the bladder

               -  Locally advanced or metastatic disease

          -  Unidimensionally measurable disease by physical exam or imaging study

               -  The following are not considered measurable disease:

                    -  Bone only disease

                    -  Pleural or peritoneal effusions

                    -  CNS lesions

                    -  Irradiated lesions unless disease progression was documented after
                       radiotherapy

          -  Not amenable to surgery

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 2.0 mg/dL

        Renal

          -  Creatinine ≤ 2.0 mg/dL

        Gastrointestinal

          -  No active inflammatory bowel disease

          -  No significant bowel obstruction

          -  No chronic diarrhea

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other active malignancy except nonmelanoma skin cancer

          -  No mental incapacitation or psychiatric illness that would preclude giving informed
             consent

          -  No other severe disease that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)

        Chemotherapy

          -  No more than 1 prior platinum-based chemotherapy regimen

          -  At least 4 weeks since prior chemotherapy

          -  No prior irinotecan or gemcitabine

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No concurrent hormones except steroids for adrenal failure, hormones for
             non-disease-related conditions (e.g., insulin for diabetes), and intermittent
             dexamethasone as an antiemetic

        Radiotherapy

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent palliative radiotherapy

        Surgery

          -  Not specified

        Other

          -  No concurrent participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uzair B. Chaudhary, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Leone</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina, Hollings Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <results_first_submitted>May 4, 2018</results_first_submitted>
  <results_first_submitted_qc>June 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine and Irnotecan</title>
          <description>On day 1 and day 8 of each 21 day cycle:
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine and Irnotecan</title>
          <description>On day 1 and day 8 of each 21 day cycle:
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Proportion</title>
        <time_frame>From registration until time of complete response or partial response</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Irnotecan</title>
            <description>On day 1 and day 8 of each 21 day cycle:
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Response Proportion</title>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>From registration until disease progression among patients who had at least a partial response.</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Irnotecan</title>
            <description>On day 1 and day 8 of each 21 day cycle:
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events as Assessed by NCI CTC Version 2.0</title>
        <time_frame>From the day of first dose until the end of study, an average of 6 months</time_frame>
        <population>data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Irnotecan</title>
            <description>On day 1 and day 8 of each 21 day cycle:
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events as Assessed by NCI CTC Version 2.0</title>
          <population>data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Time between registration and disease progression or death, whichever comes first.</time_frame>
        <population>data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine and Irnotecan</title>
            <description>On day 1 and day 8 of each 21 day cycle:
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from start of treatment until end of study, an average of 6 months</time_frame>
      <desc>The data for this endpoint was not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine and Irnotecan</title>
          <description>On day 1 and day 8 of each 21 day cycle:
gemcitabine hydrochloride 1,000 mg/m2 IV over 30 minutes
irinotecan hydrochloride 100mg/m2 IV over 90 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kate Anderton</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-2708</phone>
      <email>anderton@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

